<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neural Transm (Vienna)</journal-id><journal-id journal-id-type="iso-abbrev">J Neural Transm (Vienna)</journal-id><journal-title-group><journal-title>Journal of Neural Transmission</journal-title></journal-title-group><issn pub-type="ppub">0300-9564</issn><issn pub-type="epub">1435-1463</issn><publisher><publisher-name>Springer Vienna</publisher-name><publisher-loc>Vienna</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28213761</article-id><article-id pub-id-type="pmc">5399046</article-id><article-id pub-id-type="publisher-id">1694</article-id><article-id pub-id-type="doi">10.1007/s00702-017-1694-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Translational Neurosciences - Short communication</subject></subj-group></article-categories><title-group><article-title>Psychomotor effect differences between <italic>l</italic>-methamphetamine and <italic>d</italic>-methamphetamine are independent of murine plasma and brain pharmacokinetics profiles</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5482-5276</contrib-id><name><surname>Nishimura</surname><given-names>Tetsuya</given-names></name><address><phone>+81-72-332-5151</phone><email>soyaku@fujimoto-pharm.co.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Takahata</surname><given-names>Kazue</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Kosugi</surname><given-names>Yuri</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Tanabe</surname><given-names>Takaaki</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Muraoka</surname><given-names>Shizuko</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.418038.6</institution-id><institution>Department of Scientific Research, </institution><institution>Fujimoto Pharmaceutical Corporation, </institution></institution-wrap>1-3-40 Nishiotsuka, Matsubara, Osaka 580-8503 Japan </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>2</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>2</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>124</volume><issue>5</issue><fpage>519</fpage><lpage>523</lpage><history><date date-type="received"><day>6</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>31</day><month>1</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p>
<italic>l</italic>-Methamphetamine has been occasionally referred to as a stimulant similar to <italic>d</italic>-methamphetamine, probably owing to insufficient comparative studies. Here, we directly compared psychomotor efficacies and pharmacokinetics of methamphetamine enantiomers in mice. Only <italic>d</italic>-methamphetamine, but not <italic>l</italic>-methamphetamine, induced stereotypy and sensitization at 1&#x02013;10&#x000a0;mg/kg. However, plasma pharmacokinetic parameters of 10&#x000a0;mg/kg <italic>l</italic>-methamphetamine were &#x02265;tenfold those of 1&#x000a0;mg/kg <italic>d</italic>-methamphetamine. These results clearly indicate that differential psychomotor efficacies of methamphetamine enantiomers are independent of their pharmacokinetic profiles.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Methamphetamine</kwd><kwd>Enantiomer</kwd><kwd>Pharmacokinetics</kwd><kwd>Psychomotor</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Wien 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Methamphetamine is a highly addictive stimulant, and its psychostimulant effects have been suggested to be attributable to its stimulating action on presynaptic neurons, resulting in a release of dopamine and other neurotransmitters through monoamine transporters or vesicular monoamine transporters (Barr et al. <xref ref-type="bibr" rid="CR1">2006</xref>). Methamphetamine, having a chiral center, exists as <italic>d</italic>- and <italic>l</italic>-enantiomers and is designated as a controlled substance without discrimination of its enantiomers. The <italic>d</italic>-enantiomer exerts potent physiological and psychostimulant effects and has high abuse liability, whereas the <italic>l</italic>-enantiomer exerts almost none of these effects (Mendelson et al. <xref ref-type="bibr" rid="CR6">2006</xref>). In clinical practice, <italic>d</italic>-methamphetamine is prescribed for treatment of attention-deficit/hyperactivity disorder, exogenous obesity, and narcolepsy. <italic>l</italic>-Methamphetamine is an active ingredient contained in a nasal decongestant (Vicks Vapor Inhaler) in the United States and is a metabolite of selegiline, a selective monoamine oxidase (MAO)-B inhibitor widely used for treatment of Parkinson&#x02019;s disease and depression. <italic>l</italic>-Methamphetamine has often been described as a molecule with pharmacological efficacy comparable to <italic>d</italic>-methamphetamine, likely because only a few comparative pharmacodynamic and pharmacokinetic studies have been conducted. Therefore, selegiline, sometimes ambiguously referred to as its major metabolite <italic>l</italic>-methamphetamine, may also induce psychostimulant effects.</p><p>The aim of the present study was to determine the efficacies of the methamphetamine enantiomers to induce psychostimulant effects, and to clarify a cause for any differences. Some pharmacological response differences are related to pharmacokinetic properties. For instance, a comparative study on <italic>d</italic>-methamphetamine and cocaine revealed that the slower clearance of <italic>d</italic>-methamphetamine contributes to the longer-lasting stimulant effects (Fowler et al. <xref ref-type="bibr" rid="CR4">2007</xref>). Thus, in the present study, we directly compared the psychomotor effects and pharmacokinetics of the methamphetamine enantiomers in mice.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Animals</title><p>Male ddY mice (8&#x000a0;weeks old, Japan SLC, Shizuoka, Japan) were kept in a facility with controlled humidity (50&#x000a0;&#x000b1;&#x000a0;20%) and temperature (23&#x000a0;&#x000b1;&#x000a0;2&#x000a0;&#x000b0;C) and were maintained under a 12-h light/dark cycle with free access to food (Oriental Yeast, Tokyo, Japan) and water. The mice were acclimated for 1&#x000a0;week before being used in the experiments.</p></sec><sec id="Sec4"><title>Chemicals</title><p>
<italic>l</italic>-Methamphetamine hydrochloride was prepared from benzaldehyde in our institution according to previously described methods (Paulsen-S&#x000f6;rman et al. <xref ref-type="bibr" rid="CR8">1984</xref>; Posakony et al. <xref ref-type="bibr" rid="CR9">2002</xref>). The purity of the product was &#x0003e;99%. <italic>d</italic>-Methamphetamine hydrochloride was purchased from Dainippon Pharmaceutical (Osaka, Japan). All reagents were dissolved in saline and administered subcutaneously (s.c.).</p></sec><sec id="Sec5"><title>Locomotor activity</title><p>Locomotor activity was measured for 2&#x000a0;h post-drug administration using an infrared-linked activity sensor system (AB System-24A, Neuroscience, Tokyo). For sensitization, each mouse was treated with one of the enantiomers at an interval of 3 or 4&#x000a0;days, for a total of seven injections. Locomotor activity in these mice was also measured for 2&#x000a0;h post-drug administration.</p></sec><sec id="Sec6"><title>Stereotyped behavior</title><p>The intensity of stereotyped behavior was assessed at 15-min intervals for 2&#x000a0;h post-drug administration using the scoring system of Costall and Naylor (<xref ref-type="bibr" rid="CR3">1973</xref>): 0, behavior of the mouse is the same as that of a saline-treated mouse; 1, discontinuous sniffing with constant exploratory activity; 2, continuous sniffing and periodic exploratory activity; 3, continuous sniffing and discontinuous biting, gnawing or licking; 4, continuous biting, gnawing or licking, with no exploratory activity.</p></sec><sec id="Sec7"><title>Pharmacokinetics</title><p>A blood sample (20&#x000a0;&#x003bc;L) was collected from tail vein at indicated time points in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, and stored at &#x02212;20&#x000a0;&#x000b0;C after centrifugation (12,000&#x000d7;<italic>g</italic>, 5&#x000a0;min). The striatum was dissected out 2&#x000a0;h after administration and stored at &#x02212;80&#x000a0;&#x000b0;C. Striatal samples were homogenized in 50% acetonitrile, and centrifuged (10,400&#x000d7;<italic>g</italic>, 15&#x000a0;min, 4&#x000a0;&#x000b0;C). Each sample was extracted with 1-chlolobutane/acetonitrile (4/1, v/v), then with 0.5% HCl (back extraction). Amphetamine and methamphetamine concentrations were determined by liquid chromatography&#x02013;tandem-mass spectrometry (Slawson et al. <xref ref-type="bibr" rid="CR11">2002</xref>) with a Chromolith RP-18e column (Merck, Darmstadt, Germany), without chiral derivatization (Nishida et al. <xref ref-type="bibr" rid="CR7">2006</xref>). The lower limit of quantification was 3&#x000a0;ng/mL, but for brain amphetamine, 1&#x000a0;ng/mL. The maximum plasma concentration (<italic>C</italic>
<sub>max</sub>) and the area under the plasma concentration vs. time curve from 0 to 2 or 4&#x000a0;h (AUC<sub>0&#x02013;2h</sub> or AUC<sub>0&#x02013;4h</sub>) were calculated using WinNonlin software version 6.4 (Certara, NJ, USA).</p></sec><sec id="Sec8"><title>Statistical analysis</title><p>Statistical analyses were performed using one-way analysis of variance with SPSS Statistics software (IBM Corp., NY, USA), followed by Dunnett&#x02019;s test (locomotor activity and stereotypy), the Bonferroni correction (sensitization), or Student&#x02019;s <italic>t</italic> test (pharmacokinetics). Differences were considered statistically significant at values of <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05.</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Comparison of methamphetamine enantiomer-induced psychomotor effects</title><p>Subcutaneous administration of <italic>l</italic>-methamphetamine at doses of 1&#x02013;10&#x000a0;mg/kg did not significantly increase locomotor activity in mice (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). By contrast, administration of <italic>d</italic>-methamphetamine at doses of 1&#x02013;3&#x000a0;mg/kg&#x000a0;led to dose-dependent increases in locomotor activity. Although marked increases in locomotor activity were measured during the first 10&#x000a0;min following administration of <italic>d</italic>-methamphetamine at 10&#x000a0;mg/kg, this dose did not significantly augment cumulative locomotor activity during the entire 2-h period (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b). However, <italic>d</italic>-methamphetamine-treated mice showed intense stereotyped behaviors (e.g., biting or licking) without traveling, even beyond the 2-h period. The stereotyped behaviors were evaluated at the same doses. <italic>d</italic>-Methamphetamine induced stereotyped behaviors in a dose-dependent manner, whereas <italic>l</italic>-methamphetamine did not (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c). This result suggests that the decreased locomotor activity in mice treated with 10&#x000a0;mg/kg of <italic>d</italic>-methamphetamine may be due to the induction of strong stereotyped behaviors. Moreover, mice repeatedly administered <italic>l</italic>-methamphetamine did not develop behavioral sensitization, whereas repeated exposure to <italic>d</italic>-methamphetamine led to hyperlocomotion at a level exceeding that induced following the initial administration (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>d).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>
<italic>d</italic>-Methamphetamine, but not <italic>l</italic>-methamphetamine, at doses of 1&#x02013;10&#x000a0;mg/kg induces psychomotor activity. Cumulative counts (<bold>a</bold>) and temporal change (<bold>b</bold>) in locomotor activity in mice for 2&#x000a0;h following a single administration of saline, <italic>l</italic>-methamphetamine (<italic>l</italic>-MAMP), or <italic>d</italic>-methamphetamine (<italic>d</italic>-MAMP) at doses of 1&#x02013;10&#x000a0;mg/kg. <bold>c</bold> Cumulative 2-h scores for stereotyped behaviors in mice treated with <italic>l</italic>- or <italic>d</italic>-methamphetamine (1&#x02013;10&#x000a0;mg/kg). <bold>d</bold> Sensitization following repeated administration of <italic>l</italic>- or <italic>d</italic>-methamphetamine (2&#x000a0;mg/kg). Each value represents mean&#x000a0;&#x000b1;&#x000a0;SEM (<bold>a</bold>, <bold>c</bold>, and <bold>d</bold>) or mean (<bold>b</bold>). (<bold>a</bold> and <bold>b</bold>, <italic>n</italic>&#x000a0;=&#x000a0;12; <bold>c</bold>, <italic>n</italic>&#x000a0;=&#x000a0;9; <bold>d</bold>, <italic>n</italic>&#x000a0;=&#x000a0;7&#x02013;8). *<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, **<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.005 and ***<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0005 vs. saline-treated mice (<bold>a</bold>, <bold>c</bold>), or vs. the first administration in each group (<bold>d</bold>)</p></caption><graphic xlink:href="702_2017_1694_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec11"><title>Pharmacokinetics</title><p>We next investigated whether differences in plasma or brain pharmacokinetic parameters reflected the intensity of the psychomotor effects. Values of plasma <italic>C</italic>
<sub>max</sub> and AUC<sub>0&#x02013;4h</sub> following administration of 1&#x000a0;mg/kg <italic>d</italic>-methamphetamine were comparable with those for 1&#x000a0;mg/kg&#x000a0;<italic>l</italic>-methamphetamine (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Mice were administered 1&#x000a0;mg/kg of <italic>d</italic>-methamphetamine s.c. (a dose that induced psychomotor activity) or 10&#x000a0;mg/kg (s.c.) of <italic>l</italic>-methamphetamine (the maximum dose used in the behavioral tests). Plasma <italic>C</italic>
<sub>max</sub>, AUC<sub>0&#x02013;2h</sub>, and striatal concentrations of methamphetamine and amphetamine following administration of <italic>l</italic>-methamphetamine were &#x02265;10-fold those post <italic>d</italic>-methamphetamine administration. These results indicate that the distinctive psychomotor effects of <italic>d</italic>- and <italic>l</italic>-methamphetamine are not due to differences in their plasma or striatum pharmacokinetics.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Pharmacokinetic parameters and brain concentrations of methamphetamine and amphetamine in mice following subcutaneous administration of <italic>l</italic>-methamphetamine or <italic>d</italic>-methamphetamine</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Exp. no.</th><th align="left">Tissue</th><th align="left">Analyte</th><th align="left">Parameter</th><th align="left" colspan="2">Drug administered</th></tr></thead><tbody><tr><td align="left" colspan="4"/><td align="left">
<italic>l</italic>-MAMP (1&#x000a0;mg/kg)</td><td align="left">
<italic>d</italic>-MAMP (1&#x000a0;mg/kg)</td></tr><tr><td align="left" rowspan="2">I</td><td align="left" rowspan="2">Plasma</td><td align="left" rowspan="2">MAMP</td><td align="left">
<italic>C</italic>
<sub>max</sub> (&#x003bc;g/mL)</td><td align="left">0.062&#x000a0;&#x000b1;&#x000a0;0.007</td><td align="left">0.072&#x000a0;&#x000b1;&#x000a0;0.013</td></tr><tr><td align="left">AUC<sub>0&#x02013;4&#x000a0;h</sub> (&#x003bc;g&#x000b7;h/mL)</td><td char="." align="left">0.129</td><td char="." align="left">0.159</td></tr><tr><td align="left" colspan="4"/><td align="left">
<italic>l</italic>-MAMP (10&#x000a0;mg/kg)</td><td align="left">
<italic>d</italic>-MAMP (1&#x000a0;mg/kg)</td></tr><tr><td align="left" rowspan="6">II</td><td align="left" rowspan="4">Plasma</td><td align="left" rowspan="2">MAMP</td><td align="left">
<italic>C</italic>
<sub>max</sub> (&#x003bc;g/mL)</td><td char="&#x000b1;" align="left">0.988&#x000a0;&#x000b1;&#x000a0;0.034*</td><td char="&#x000b1;" align="left">0.093&#x000a0;&#x000b1;&#x000a0;0.008</td></tr><tr><td align="left">AUC<sub>0&#x02013;2&#x000a0;h</sub> (&#x003bc;g&#x000b7;h/mL)</td><td char="&#x000b1;" align="left">1.66&#x000a0;&#x000b1;&#x000a0;0.06*</td><td char="&#x000b1;" align="left">0.142&#x000a0;&#x000b1;&#x000a0;0.008</td></tr><tr><td align="left" rowspan="2">AMP</td><td align="left">
<italic>C</italic>
<sub>max</sub> (&#x003bc;g/mL)</td><td char="&#x000b1;" align="left">0.067&#x000a0;&#x000b1;&#x000a0;0.005</td><td align="left">&#x0003c;0.003<sup>a</sup>
</td></tr><tr><td align="left">AUC<sub>0&#x02013;2&#x000a0;h</sub> (&#x003bc;g&#x000b7;h/mL)</td><td char="&#x000b1;" align="left">0.092&#x000a0;&#x000b1;&#x000a0;0.008</td><td align="left">N.C.</td></tr><tr><td align="left" rowspan="2">Brain</td><td align="left">MAMP</td><td align="left">Conc. (&#x003bc;g/g tissue)</td><td char="&#x000b1;" align="left">1.99&#x000a0;&#x000b1;&#x000a0;0.06*</td><td char="&#x000b1;" align="left">0.126&#x000a0;&#x000b1;&#x000a0;0.008</td></tr><tr><td align="left">AMP</td><td align="left">Conc. (&#x003bc;g/g tissue)</td><td char="&#x000b1;" align="left">0.212&#x000a0;&#x000b1;&#x000a0;0.013*</td><td char="&#x000b1;" align="left">0.006&#x000a0;&#x000b1;&#x000a0;0.001</td></tr></tbody></table><table-wrap-foot><p>Blood samples were collected at 0.08, 0.17, 0.33, 0.5, 1, 1.5, 2, 3 and 4&#x000a0;h (Exp. I), and 0.17, 0.33, 0.5, 1, 1.5, and 2&#x000a0;h (Exp. II) post-drug administration. Each value represents mean or mean&#x000a0;&#x000b1;&#x000a0;SD (3&#x02013;4 mice per time-point; Exp. I), or mean&#x000a0;&#x000b1;&#x000a0;SEM (6 mice per group; Exp. II)</p><p>
<italic>MAMP</italic> methamphetamine, <italic>AMP</italic> amphetamine, <italic>AUC</italic>
<sub><italic>0&#x02013;2h</italic></sub>
<italic>and AUC</italic>
<sub><italic>0&#x02013;4h</italic></sub> area under the plasma concentration vs. time curve from 0 to 2 or 4&#x000a0;h, <italic>C</italic>
<sub><italic>max</italic></sub> maximum plasma concentration, <italic>Conc.</italic> concentration, <italic>N.C.</italic> not calculated</p><p>*&#x000a0;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 vs. <italic>d</italic>-methamphetamine-treated group</p><p>
<sup>a</sup>Below the lower limit of quantitation (3&#x000a0;ng/mL)</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec12"><title>Discussion</title><p>There have been no studies directly comparing the pharmacodynamics and pharmacokinetics of the methamphetamine enantiomers in mice. It is often suggested that <italic>d</italic>-methamphetamine exerts more potent physiological and pharmacological effects than <italic>l</italic>-methamphetamine does, and that the stimulating effects exerted by <italic>l</italic>-methamphetamine on the central nervous system are 2&#x02013;10 times less potent than those of <italic>d</italic>-methamphetamine (Mendelson et al. <xref ref-type="bibr" rid="CR6">2006</xref>). The results of the present study indicated that psychostimulant effects induced by <italic>l</italic>-methamphetamine are lower than those elicited by one-tenth the dose of <italic>d</italic>-methamphetamine. In addition, plasma pharmacokinetic parameters and striatal concentrations of methamphetamine following administration of <italic>l</italic>-methamphetamine at 10&#x000a0;mg/kg (which did not induce psychomotor activity) were approximately 11 and 16 times as high, respectively, as those following administration of 1&#x000a0;mg/kg <italic>d</italic>-methamphetamine. Despite the fact that there are differentiable psycho-stimulating effects between two enantiomers, no significant difference in plasma pharmacokinetic parameters was detected at 1&#x000a0;mg/kg. In comparative positron emission tomography studies, the pharmacokinetics in the baboon brain was comparable for <sup>11</sup>C-<italic>d</italic>- and <sup>11</sup>C-<italic>l</italic>-methamphetamine (Fowler et al. <xref ref-type="bibr" rid="CR4">2007</xref>). Thus, factors other than brain or plasma pharmacokinetics, especially differences in the affinity of each enantiomer for its pharmacological targets, may account for the more potent psychomotor effects of <italic>d</italic>-methamphetamine. For instance, the effects of <italic>d</italic>-methamphetamine on the release and uptake of dopamine in rat caudate synaptosomes are reportedly approximately 17- and 42-fold greater, respectively, than those of <italic>l</italic>-methamphetamine (Rothman et al. <xref ref-type="bibr" rid="CR10">2001</xref>). Kuzcenski et al. (<xref ref-type="bibr" rid="CR5">1995</xref>) demonstrated that the peak dopamine concentration in rat caudate following s.c. administration of 2&#x000a0;mg/kg <italic>d</italic>-methamphetamine is approximately 2.3 times as high as that after administration of 12&#x000a0;mg/kg <italic>l</italic>-methamphetamine. Comparative studies to differentiate the affinities of the enantiomers to target molecules will be required to clarify the mechanisms that give rise to the difference in psychomotor efficacies between <italic>d</italic>- and <italic>l</italic>-methamphetamine.</p><p>Selegiline is sometimes regarded as an inducer of psychoactive effects through its metabolites having a component of <italic>N</italic>,&#x003b1;-dimethyl-<italic>N</italic>-2-propynyl phenethylamine. Previous clinical studies have reported that the <italic>C</italic>
<sub>max</sub> of <italic>l</italic>-methamphetamine following administration of conventional selegiline tablets 10&#x000a0;mg (Clarke et al. <xref ref-type="bibr" rid="CR2">2003</xref>) was fivefold lower than the <italic>C</italic>
<sub>max</sub> observed in methamphetamine abusers who had received intravenous <italic>l</italic>-methamphetamine at a dose of 0.25&#x000a0;mg/kg, which does not exert psychoactive effects (Mendelson et al. <xref ref-type="bibr" rid="CR6">2006</xref>). Thus, the results of these previous reports suggest that the <italic>l</italic>-methamphetamine available as a metabolite after selegiline administration at clinical doses may have little potential to induce psychoactive effects.</p><p>Taken together, our results indicated that the psychostimulant effects elicited by <italic>d</italic>-methamphetamine are at least 10 times stronger than those induced by <italic>l</italic>-methamphetamine based on their doses for inducing psychomotor activities. Furthermore, the distinct psychoactive efficacies of the enantiomers are not due to differences in plasma pharmacokinetics or brain concentrations of methamphetamine/amphetamine following administration of the respective enantiomers.
</p></sec></body><back><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><sec id="FPar1"><title>Conflict of interest</title><p>All authors are employees of Fujimoto Pharmaceutical Corporation.</p></sec><sec id="FPar2"><title>Ethical approval</title><p>All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barr</surname><given-names>AM</given-names></name><name><surname>Panenka</surname><given-names>WJ</given-names></name><name><surname>MacEwan</surname><given-names>GW</given-names></name><name><surname>Thornton</surname><given-names>AE</given-names></name><name><surname>Lang</surname><given-names>DJ</given-names></name><name><surname>Honer</surname><given-names>WG</given-names></name><name><surname>Lecomte</surname><given-names>T</given-names></name></person-group><article-title>The need for speed: an update on methamphetamine addiction</article-title><source>J Psychiatry Neurosci</source><year>2006</year><volume>31</volume><issue>5</issue><fpage>301</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">16951733</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>A</given-names></name><name><surname>Brewer</surname><given-names>F</given-names></name><name><surname>Johnson</surname><given-names>ES</given-names></name><name><surname>Mallard</surname><given-names>N</given-names></name><name><surname>Hartig</surname><given-names>F</given-names></name><name><surname>Taylor</surname><given-names>S</given-names></name><name><surname>Corn</surname><given-names>TH</given-names></name></person-group><article-title>A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition</article-title><source>J Neural Transm (Vienna)</source><year>2003</year><volume>110</volume><issue>11</issue><fpage>1241</fpage><lpage>1255</lpage><pub-id pub-id-type="doi">10.1007/s00702-003-0036-4</pub-id><pub-id pub-id-type="pmid">14628189</pub-id></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costall</surname><given-names>B</given-names></name><name><surname>Naylor</surname><given-names>RJ</given-names></name></person-group><article-title>The role of telencephalic dopaminergic systems in the mediation of apomorphine-stereotyped behaviour</article-title><source>Eur J Pharmacol</source><year>1973</year><volume>24</volume><issue>1</issue><fpage>8</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(73)90108-8</pub-id><pub-id pub-id-type="pmid">4796448</pub-id></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fowler</surname><given-names>JS</given-names></name><name><surname>Kroll</surname><given-names>C</given-names></name><name><surname>Ferrieri</surname><given-names>R</given-names></name><name><surname>Alexoff</surname><given-names>D</given-names></name><name><surname>Logan</surname><given-names>J</given-names></name><name><surname>Dewey</surname><given-names>SL</given-names></name><name><surname>Schiffer</surname><given-names>W</given-names></name><name><surname>Schlyer</surname><given-names>D</given-names></name><name><surname>Carter</surname><given-names>P</given-names></name><name><surname>King</surname><given-names>P</given-names></name><name><surname>Shea</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Muench</surname><given-names>L</given-names></name><name><surname>Benveniste</surname><given-names>H</given-names></name><name><surname>Vaska</surname><given-names>P</given-names></name><name><surname>Volkow</surname><given-names>ND</given-names></name></person-group><article-title>PET studies of <italic>d</italic>-methamphetamine pharmacokinetics in primates: comparison with <italic>l</italic>-methamphetamine and (-)-cocaine</article-title><source>J Nucl Med</source><year>2007</year><volume>48</volume><issue>10</issue><fpage>1724</fpage><lpage>1732</lpage><pub-id pub-id-type="doi">10.2967/jnumed.107.040279</pub-id><pub-id pub-id-type="pmid">17873134</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuczenski</surname><given-names>R</given-names></name><name><surname>Segal</surname><given-names>DS</given-names></name><name><surname>Cho</surname><given-names>AK</given-names></name><name><surname>Melega</surname><given-names>W</given-names></name></person-group><article-title>Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine</article-title><source>J Neurosci</source><year>1995</year><volume>15</volume><issue>2</issue><fpage>1308</fpage><lpage>1317</lpage><pub-id pub-id-type="pmid">7869099</pub-id></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendelson</surname><given-names>J</given-names></name><name><surname>Uemura</surname><given-names>N</given-names></name><name><surname>Harris</surname><given-names>D</given-names></name><name><surname>Nath</surname><given-names>RP</given-names></name><name><surname>Fernandez</surname><given-names>E</given-names></name><name><surname>Jacob</surname><given-names>P</given-names><suffix>3rd</suffix></name><name><surname>Everhart</surname><given-names>ET</given-names></name><name><surname>Jones</surname><given-names>RT</given-names></name></person-group><article-title>Human pharmacology of the methamphetamine stereoisomers</article-title><source>Clin Pharmacol Ther</source><year>2006</year><volume>80</volume><issue>4</issue><fpage>403</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1016/j.clpt.2006.06.013</pub-id><pub-id pub-id-type="pmid">17015058</pub-id></element-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishida</surname><given-names>K</given-names></name><name><surname>Itoh</surname><given-names>S</given-names></name><name><surname>Inoue</surname><given-names>N</given-names></name><name><surname>Kudo</surname><given-names>K</given-names></name><name><surname>Ikeda</surname><given-names>N</given-names></name></person-group><article-title>High-performance liquid chromatographic&#x02013;mass spectrometric determination of methamphetamine and amphetamine enantiomers, desmethylselegiline and selegiline, in hair samples of long-term methamphetamine abusers or selegiline users</article-title><source>J Anal Toxicol</source><year>2006</year><volume>30</volume><issue>4</issue><fpage>232</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1093/jat/30.4.232</pub-id><pub-id pub-id-type="pmid">16803660</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paulsen-S&#x000f6;rman</surname><given-names>UB</given-names></name><name><surname>J&#x000f6;nsson</surname><given-names>KH</given-names></name><name><surname>Lindeke</surname><given-names>BG</given-names></name></person-group><article-title>Cytochrome P-455 nm complex formation in the metabolism of phenylalkylamines. 8. Stereoselectivity in metabolic intermediary complex formation with a series of chiral 2-substituted 1-phenyl-2-aminoethanes</article-title><source>J Med Chem</source><year>1984</year><volume>27</volume><issue>3</issue><fpage>342</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1021/jm00369a018</pub-id><pub-id pub-id-type="pmid">6699879</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posakony</surname><given-names>JJ</given-names></name><name><surname>Grierson</surname><given-names>JR</given-names></name><name><surname>Tewson</surname><given-names>TJ</given-names></name></person-group><article-title>New routes to <italic>N</italic>-alkylated cyclic sulfamidates</article-title><source>J Org Chem</source><year>2002</year><volume>67</volume><issue>15</issue><fpage>5164</fpage><lpage>5169</lpage><pub-id pub-id-type="doi">10.1021/jo0157019</pub-id><pub-id pub-id-type="pmid">12126401</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothman</surname><given-names>RB</given-names></name><name><surname>Baumann</surname><given-names>MH</given-names></name><name><surname>Dersch</surname><given-names>CM</given-names></name><name><surname>Romero</surname><given-names>DV</given-names></name><name><surname>Rice</surname><given-names>KC</given-names></name><name><surname>Carroll</surname><given-names>FI</given-names></name><name><surname>Partilla</surname><given-names>JS</given-names></name></person-group><article-title>Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin</article-title><source>Synapse</source><year>2001</year><volume>39</volume><issue>1</issue><fpage>32</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1002/1098-2396(20010101)39:1&#x0003c;32::AID-SYN5&#x0003e;3.0.CO;2-3</pub-id><pub-id pub-id-type="pmid">11071707</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slawson</surname><given-names>MH</given-names></name><name><surname>Taccogno</surname><given-names>JL</given-names></name><name><surname>Foltz</surname><given-names>RL</given-names></name><name><surname>Moody</surname><given-names>DE</given-names></name></person-group><article-title>Quantitative analysis of selegiline and three metabolites (<italic>N</italic>-desmethylselegiline, methamphetamine, and amphetamine) in human plasma by high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry</article-title><source>J Anal Toxicol</source><year>2002</year><volume>26</volume><issue>7</issue><fpage>430</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1093/jat/26.7.430</pub-id><pub-id pub-id-type="pmid">12422997</pub-id></element-citation></ref></ref-list></back></article>